Skip to content

Author

David F. Stroncek

We have 3 of 63 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Transduction efficiency in clinical CAR T cell products: A retrospective study at a single center

Transduction efficiency (TE) is a key measure of CAR T cell manufacturing quality; however, its variability and relationship to the final product phenotype remain incompletely understood. In this retrospective study, we evaluated TE across 204 GMP-manufactured CAR T cell products, integrating manufacturing parameters,...

L. Shao, M. Procházková, Yi-Hua Cai et al. · 0 citations
Review Open access Sep 2026

In Vivo CAR-T Cell Engineering: Translating Vector Pharmacology into Therapeutic Performance

A Quality-by-Design (QbD) framework is proposed-a systematic, science- and risk-based development approach that begins with predefined product objectives and links critical quality attributes to material attributes and process controls and discusses development pathways that emphasize platform–indication matching, inna...

David F. Stroncek, Jia-Qiang Ren, Anh Dinh · 0 citations
Open access Jul 2026

Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood

Compared to the standard 7-day method, the 3-day approach resulted in expression of genes associated with a more stem-like phenotype while reducing manufacturing time and cost, and may provide a practical alternative for decentralized CAR T-cell manufacturing, particularly in resource-limited settings.

Isabella Vignola, M. Procházková, L. Shao et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.